BiotechTube
Faberge Fertility

Faberge Fertility

New York, United States· Est.
fabergefertility.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Faberge Fertility is an early-stage biotech company founded in 2020, operating at the intersection of reproductive health and digital health. Its core innovation is the Precision ETS, a medical device aimed at enhancing the precision and success of embryo transfers during IVF procedures. The company is supported by the University of Minnesota's startup ecosystem and the Red Wing Ignite incubator, with a leadership team combining clinical and engineering expertise. It is currently pre-revenue and in the development phase, seeking regulatory approval for its novel system.

Reproductive HealthFertility

Technology Platform

Precision ETS (Embryo Transplant System) - a patent-pending medical device system designed to improve the precision and outcomes of embryo transfer during IVF procedures.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The global IVF market is large and growing, driven by delayed parenthood and rising infertility rates.
A device that demonstrably improves pregnancy rates and reduces costly, dangerous ectopic pregnancies would address a significant unmet need and see strong demand from clinics competing on success metrics.
Success could position the company as an attractive acquisition target for larger medtech or fertility companies.

Risk Factors

The company faces high regulatory risk as the product requires FDA clearance, which is not guaranteed.
As a single-product, pre-revenue startup, it carries significant technical risk that the device will perform as intended in clinical settings and financial risk in securing the capital needed to reach commercialization.
It must also overcome adoption barriers in a competitive market with established transfer protocols.

Competitive Landscape

The competitive landscape includes companies offering embryo transfer catheters (e.g., CooperSurgical, Cook Medical) and emerging technologies in embryo selection (AI-based imaging) and uterine receptivity testing. Faberge's direct competition would be from other specialized transfer devices or guidance systems. Its success hinges on demonstrating superior clinical outcomes compared to these existing, standard-of-care tools.

More companies in Regenerative Medicine →More companies in United States →